A Bacillus stearothermophilus var. calidolactis C953 tube test was evaluated for its ability in detecting the residue of selected anticoccidial drugs in poultry, specically sulfamethazine, furazolidone, and amprolium. Various concentrations of each drug were injected into chicken liver and kidney tissues and these tissues were tested to determine the drug detection limits for each drug. The detection limit was defined as the drug concentration at which 95% of the test results were interpreted as positive. The limits of detection in liver tissue were 0.35 microgram/ml for furazolidone, 0.70 microgram/ml for sulfamethazine and 7.80 microgram/ ml for amprolium. In kidney tissues, they were 0.30 microgram/ml for furazolidone, 0.54 microgram/ml for sulfamethazine, and 7.6 microgram/ml for amprolium. It was concluded that this tube test could be used to screen for the residue of these three drugs in poultry.
Amprolium/analysis ; Animals ; Bacillus stearothermophilus/*drug effects ; Coccidiostats/*analysis ; Drug Residues/*analysis ; Furazolidone/analysis ; Kidney/chemistry ; Liver/chemistry ; *Poultry ; Sulfamethazine/analysis

OBJECTIVE: To examine the infection and bacteria resistance of Helicobacter pylori (H.pylori) to clarithromycin and furazolidone,to determine whether the antibiotic resistance is primary or secondary, and to decide if a new H.pylori infection plays a role in eradication failures. METHODS: Twenty one H.pylori had been isolated from human biopsy specimens, and antimicrobial susceptibility testing was performed. DNA fingerprints were generated using random amplification polymorphic DNA (RAPD) to determine the identity of H.pylori before and after the eradication therapy. RESULTS: Eight bacteria resisted against clarithromycin, and one against furazolidone, with the resistant rates 38.1% and 4.8% respectively. The number of primary antibiotic resistance, secondary resistance and new infection was 1 for each. CONCLUSION Resistance to clarithromycin is more common compared with that to furazolidone. Development of primary and secondary resistance to clarithromycin occurs as a rule in eradication failures. New H.pylori infection plays a role in eradication failures.
Anti-Bacterial Agents ; pharmacology ; therapeutic use ; Clarithromycin ; pharmacology ; therapeutic use ; DNA Fingerprinting ; DNA, Bacterial ; analysis ; genetics ; isolation & purification ; Drug Resistance, Bacterial ; Furazolidone ; pharmacology ; therapeutic use ; Helicobacter Infections ; drug therapy ; microbiology ; Helicobacter pylori ; drug effects ; genetics ; Humans ; Microbial Sensitivity Tests ; Random Amplified Polymorphic DNA Technique